Total trials
1,286
Active
197
Phase 3
41
Total enrollment
6,796,971
Pipeline matrix
Showing 38 of 38 active programs · click any cell for trials
| Intervention | Early Phase 1 | Phase 1 | Phase 2 | Phase 3 | Phase 4 | N/A | Total |
|---|---|---|---|---|---|---|---|
| Solifenacin | — | — | — | — | 2 | ||
| Mirabegron | — | — | — | — | 2 | ||
| Vaginal estradiol | — | — | — | — | — | 1 | |
| Immunoglobulin | — | — | — | — | — | 1 | |
| Aspirin | — | — | — | — | — | 1 | |
| Fondaparinux Sodium | — | — | — | — | — | 1 | |
| Intravenous furosemide continuous | — | — | — | — | — | 1 | |
| Intravenous furosemide bolus injections | — | — | — | — | — | 1 | |
| Ferric Derisomaltose | — | — | — | — | — | 1 | |
| Oral Iron | — | — | — | — | — | 1 | |
| Finerenone | — | — | — | — | — | 1 | |
| Romosozumab | — | — | — | — | — | 1 | |
| Zoledronate | — | — | — | — | — | 1 | |
| Solifenacin + Mirabegron | — | — | — | — | — | 1 | |
| Zoledronic acid 4 mg | — | — | — | — | — | 1 | |
| Natriumklorid 9 mg/ml, Fresenius Kabi | — | — | — | — | — | 1 | |
| Saline | — | — | 10 | ||||
| Phenylephrine | — | — | — | — | 2 | ||
| Tranexamic acid | — | — | — | — | — | 1 | |
| Faecal microbiota transplantation | — | — | — | — | — | 1 | |
| Noradrenalin | — | — | — | — | — | 1 | |
| Glycerol "OBA" | — | — | — | — | — | 1 | |
| Pomalidomide 2 mg | — | — | — | — | — | 1 | |
| Aspirin 75 mg | — | — | — | — | — | 1 | |
| Venetoclax | — | — | — | — | — | 1 | |
| Papilocare Vaginal Gel | — | — | — | — | — | 1 | |
| Indocyanine green | — | — | — | — | — | 2 | |
| Liver biopsy | — | — | — | — | — | 1 | |
| Lactate + mixed meal | — | — | — | — | — | 1 | |
| Mixed meal with 18F-FTHA | — | — | — | — | — | 1 | |
| Told ON | — | — | — | — | — | 1 | |
| 6-months of medically assisted glycemic improvement | — | — | — | — | — | 1 | |
| Active drug for acute migraine treatment | — | — | — | — | — | 1 | |
| Active drug for chronic migraine treatment. | — | — | — | — | — | 1 | |
| Optimal medical therapy | — | — | — | — | — | 1 | |
| Genetic risk assessment | — | — | — | — | — | 1 | |
| Growth Hormone, Human | — | — | — | — | — | 1 | |
| NOAC | — | — | — | — | — | 1 |
Next readouts
- 2025-09-30
- 2025-10-30
- 2025-12-31
- 2026-01
- 2026-01-01
- 2026-03-01
- 2026-05-31
- 2026-08
- 2026-09-01
- 2026-12
Top conditions
- Obesity27
- Healthy26
- Type 2 Diabetes22
- Stroke21
- Heart Failure20
- Diabetes Mellitus, Type 217
- Insulin Resistance17
- Multiple Sclerosis16
Frequently asked questions about University of Aarhus
- How many clinical trials does University of Aarhus have on ClinicalTrials.gov?
- University of Aarhus is listed as the lead sponsor on 1,286 clinical trials in ClinicalTrials.gov, 197 of which are currently active (recruiting, enrolling, or ongoing).
- How many of University of Aarhus's trials are in Phase 3?
- 41 of University of Aarhus's trials are in Phase 3, spread across 38 active drug programs.
- What therapeutic areas does University of Aarhus focus on?
- University of Aarhus's most-studied conditions on ClinicalTrials.gov are Obesity, Healthy, Type 2 Diabetes, Stroke, Heart Failure.
- When are University of Aarhus's next clinical trial readouts?
- University of Aarhus has 10 upcoming primary-completion readouts tracked here; the soonest is “Investigating Muscle Failure in Diabetic Myopathy”, expected around 2025-09-30.